Secukinumab in multi-failure psoriatic patients: the last hope?

M. MagnanoDepartment of Specialized, Diagnostic and Experimental Medicine University of Bologna, Italy;

C. LoiDepartment of Specialized, Diagnostic and Experimental Medicine University of Bologna, Italy; Correspondence[email protected]

A. PatriziDepartment of Specialized, Diagnostic and Experimental Medicine University of Bologna, Italy;

P. SgubbiDepartment of Specialized, Diagnostic and Experimental Medicine University of Bologna, Italy;

R. BalestriDermatology Division, Multizonale Santa Chiara Hospital, Trento, Italy;

G. RechDermatology Division, Multizonale Santa Chiara Hospital, Trento, Italy;

L TasinDermatology Division, Multizonale Santa Chiara Hospital, Trento, Italy;

C. R. GirardelliDermatology Division, Multizonale Santa Chiara Hospital, Trento, Italy;

A. ContiDermatology Unit, United Hospital of Ancona Polytechnic Marche University, Ancona, Italy;

G. OdoriciDermatology Unit, United Hospital of Ancona Polytechnic Marche University, Ancona, Italy;

A. CampanatiPsoriasis Outpatient Clinic of the Polyclinic University Hospital, Modena, Italy

A. M. OffidaniPsoriasis Outpatient Clinic of the Polyclinic University Hospital, Modena, Italy

F. BardazziDepartment of Specialized, Diagnostic and Experimental Medicine University of Bologna, Italy;

show all

References

Nast A, Gisondi P, Ormerod AD, et al. European S3-Guidelines on the systemic treatment of psoriasis vulgaris-Update 2015-Short version-EDF in cooperation with EADV and IPC. J Eur Acad Dermatol Venereol. 2015;29:2277–2294.
PubMed Web of Science ®Google Scholar
Godse K. Secukinumab - first in class interleukin-17A inhibitor for the treatment of Psoriasis. Indian J Dermatol. 2017;62:195–199.
PubMed Web of Science ®Google Scholar
Merola JF, Lockshin B, Mody EA. Switching biologics in the treatment of psoriatic arthritis. Semin Arthritis Rheum. 2017;47:29–37.
PubMed Web of Science ®Google Scholar
Kiltz U, Heldmann F, Baraliakos X, et al. Treatment of ankylosing spondylitis in patients refractory to TNF-inhibition: are there alternatives? Curr Opin Rheumatol. 2012;24:252–260.
PubMed Web of Science ®Google Scholar
Malakouti M, Jacob SE, Anderson NJ. Treatment challenges in the management of moderate-to-severe plaque psoriasis -role of secukinumab. Clin Cosmet Investig Dermatol. 2016;9:347–355.
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Secukinumab in multi-failure psoriatic patients: the last hope?

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Secukinumab in multi-failure psoriatic patients: the last hope?

References

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date